A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
I-Mab Biopharma US Limited
British Columbia Cancer Agency
Abramson Cancer Center at Penn Medicine
Dana-Farber Cancer Institute
University of Chicago
Fondazione per la Medicina Personalizzata
Hoffmann-La Roche
Jules Bordet Institute
Cambridge University Hospitals NHS Foundation Trust
National Institutes of Health Clinical Center (CC)